Novo Nordisk's Latest Clinical Result Is Sending the Stock Plunging. Here's What Investors Need to Know.

A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a reset for long-term opportunity?Novo Nordisk (NVO +1.31%) is a Danish pharmaceutical company that's been around for about a century. It specializes in developing medications for metabolic diseases, such as diabetes and obesity treatment. Most of us have probably heard of their primary products, which include Ozempic and Wegovy. Both of these treatments contain an active ingredient ca ...